Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects.

Human vaccines

Volumn 1, Issue 6, 2005, Pages 232-238

  Emery, S ^a   Workman, C ^a   Puls, R L ^a   Bloch, M ^a   Baker, D ^a   Bodsworth, N ^a   Anderson, J ^a   Crowe, S M ^a   French, M A ^a   Hoy, J ^a   Aichelburg, A ^a   Ward, L D ^a   Boyle, D B ^a   Law, M G ^a   Kelleher, A D ^a   Cooper, D A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN; RECOMBINANT VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOWLPOX VIRUS; GENE VECTOR; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; AIDS VACCINES; ANTI-HIV AGENTS; FOWLPOX VIRUS; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; VACCINES, SYNTHETIC; VIRAL LOAD;

EID: 33750611491     PISSN: 15548600     EISSN: None     Source Type: Journal    
DOI: 10.4161/hv.1.6.2342     Document Type: Article

References (0)